Security Investigation

NeoGenomics, Inc. (NasdaqCM: NEO)

8 Days left to seek lead plaintiff status.

Company Name:NeoGenomics, Inc.
Stock Symbol:NasdaqCM: NEO
Court:Southern District of New York
Class Period Start:02/27/2020
Class Period End (inclusive):04/26/2022
Filing Deadline:02/06/2023

Contact a Lawyer Now

(877) 515-1850

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM: NEO).

NeoGenomics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On March 28, 2022, the Company disclosed that its CEO was stepping down effective immediately, that it expected 1Q2022 revenue and EBITDA below the low end of its prior guidance, and that it had withdrawn its 2022 annual financial guidance.  On this news, shares of NeoGenomics fell $5.30 per share, or 29.8%. Then, on April 27, 2022, the Company disclosed its 1Q2022 financial results confirming revenue and EBITDA below its prior guidance, among other things, that the market “was moving towards larger, more comprehensive panels” and that the Company was “seeing bigger and bigger panels coming from…emerging companies . . . where we have not kept up.” On this news, shares of NeoGenomics fell $0.41 per share, or 3.8%.

If you purchased securities of NeoGenomics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.

The case is Goldenberg v. NeoGenomics, Inc., No. 22-cv-10314.

Click here to read the first filed complaint.